Clinical trials: sponsored by Arrowhead Pharmaceuticals
Homozygous Familial Hypercholesterolemia
Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
This study will evaluate the efficacy and safety of zodasiran subcutaneous (sc) injection in participants 12 to <18 years of age with genetically or clinically diagnosed homozygous familial hypercholesterolemia (HoFH) and…
- Trial name
- SPRUCE (NCT07473843)
- Testing
- Zodasiran
- Where
- 3 sites in United States, Denmark and 1 more
- Volunteers
- 10 people
- Sponsor
- Arrowhead Pharmaceuticals
Hyperlipidemia; Mixed
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and effects on low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) of single-dose ARO-DIMERPA and multiple doses of…
- Trial name
- NCT07223658
- Testing
- ARO-DIMERPA
- Where
- 19 sites in Australia, Canada and 3 more
- Volunteers
- 78 people
- Sponsor
- Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG).
- Trial name
- SHASTA-4 (NCT06347016)
- Testing
- Plozasiran Injection
- Where
- 149 sites in United States, Argentina and 14 more
- Volunteers
- 311 people
- Sponsor
- Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG).
- Trial name
- SHASTA-3 (NCT06347003)
- Testing
- Plozasiran Injection
- Where
- 196 sites in United States, Argentina and 15 more
- Volunteers
- 446 people
- Sponsor
- Arrowhead Pharmaceuticals
Metabolic Dysfunction-Associated Steatohepatitis
A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis
This study is designed to evaluate the safety and efficacy of ARO-INHBE in adults with suspected metabolic dysfunction-associated steatohepatitis (MASH).
- Trial name
- NCT07859813
- Testing
- ARO-INHBE
- Volunteers
- 252 people
- Sponsor
- Arrowhead Pharmaceuticals
Hypertriglyceridemia
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-2003…
- Trial name
- SHASTA-10 (NCT06822790)
- Testing
- Plozasiran Injection
- Where
- 253 sites in United States, Argentina and 22 more
- Volunteers
- 710 people
- Sponsor
- Arrowhead Pharmaceuticals
Asthma
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
- Trial name
- NCT07241546
- Testing
- ARO-RAGE
- Where
- 6 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Arrowhead Pharmaceuticals
Obesity
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (in Part…
- Trial name
- NCT06700538
- Testing
- ARO-INHBE, Tirzepatide
- Where
- 15 sites in Australia, Canada and 2 more
- Volunteers
- 180 people
- Sponsor
- Arrowhead Pharmaceuticals
Hypertriglyceridemia
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG).
- Trial name
- MUIR-3 (NCT06347133)
- Testing
- Plozasiran Injection
- Where
- 235 sites in United States, Argentina and 13 more
- Volunteers
- 1,456 people
- Sponsor
- Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to…
- Trial name
- SHASTA-5 (NCT06880770)
- Testing
- Plozasiran
- Where
- 140 sites in United States, Argentina and 25 more
- Volunteers
- 288 people
- Sponsor
- Arrowhead Pharmaceuticals
Alzheimer Disease, Alzheimer Disease, Early Onset
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild…
- Trial name
- NCT07221344
- Testing
- ARO-MAPT-SC
- Where
- 4 sites in Canada, New Zealand
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Age-related Macular Degeneration
A First-In-Human Study of ARO-033 in Adult Participants
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-033 compared to placebo in adult normal healthy volunteers (NHVs) and the safety…
- Trial name
- NCT07662096
- Testing
- ARO-033
- Where
- New Zealand
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Asthma, Chronic Obstructive Pulmonary Disease
Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ARO-MUC5AC in normal healthy volunteers (NHVs), patients with moderate-to-severe asthma and patients with moderate-to-severe chronic…
- Trial name
- NCT05292950
- Testing
- ARO-MUC5AC
- Where
- 13 sites in Australia, New Zealand and 5 more
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Homozygous Familial Hypercholesterolemia
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous…
- Trial name
- NCT07037771
- Testing
- zodasiran Injection
- Where
- 43 sites in United States, Australia and 16 more
- Volunteers
- 70 people
- Sponsor
- Arrowhead Pharmaceuticals
Idiopathic Pulmonary Fibrosis
Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT05537025
- Testing
- ARO-MMP7 Inhalation Solution
- Where
- 19 sites in Denmark, Italy and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Obesity, Diabetes Mellitus, Type 2
A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-ALK7 in adult participants with obesity without…
- Trial name
- NCT06937203
- Testing
- ARO-ALK7
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 150 people
- Sponsor
- Arrowhead Pharmaceuticals
Spinocerebellar Ataxia Type 2
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
Adult participants with spinocerebellar ataxia type 2 (SCA2) who carry ≥33 cytosine, adenine, guanine (CAG) repeats in the ATXN2 gene, and who have met all protocol eligibility criteria will be randomized to receive a single dose…
- Trial name
- NCT06672445
- Testing
- ARO-ATXN2 Injection
- Where
- 16 sites in Australia, Canada and 6 more
- Volunteers
- 39 people
- Sponsor
- Arrowhead Pharmaceuticals
Homozygous Familial Hypercholesterolemia
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)
Participants with documented homozygous familial hypercholesterolemia (HoFH) who have provided informed consent will receive 2 open-label doses of ARO-ANG3 and be evaluated for safety and efficacy parameters through 36 weeks.
- Trial name
- Gateway (NCT05217667)
- Testing
- ARO-ANG 3 Injection
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 18 people
- Sponsor
- Arrowhead Pharmaceuticals
Familial Chylomicronemia
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
The purpose of AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 (plozasiran) in adult participants with familial chylomicronemia syndrome (FCS).
- Trial name
- PALISADE (NCT05089084)
- Testing
- Plozasiran
- Where
- 58 sites in United States, Argentina and 19 more
- Volunteers
- 75 people
- Sponsor
- Arrowhead Pharmaceuticals
C3 Glomerulopathy, IgA Nephropathy
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
The purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patients with complement-mediated renal disease (C3 Glomerulopathy [C3G]…
- Trial name
- NCT05083364
- Testing
- ARO-C3
- Where
- 16 sites in Australia, Georgia and 5 more
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals